Propionates

• 

  Subject Areas on Research

  • 6-Hydroxydopamine injections into the nigrostriatal pathway attenuate striatal malonate and 3-nitropropionic acid lesions. 
  • A double-blind study comparing benoxaprofen, aspirin, and benoxaprofen plus aspirin in patients with rheumatoid arthritis. 
  • Acylcarnitines in amniotic fluid: application to the prenatal diagnosis of propionic acidaemia. 
  • Analysis of volatile free fatty acids in human urine by capillary column gas chromatography/mass spectrometry. 
  • Antitumor activity of creatine analogs produced by alterations in pancreatic hormones and glucose metabolism. 
  • Application of continuous-flow liquid chromatography/fast-atom bombardment mass spectrometry to the analysis of diagnostic acylcarnitines in human urine. 
  • Application of high resolution fast atom bombardment and constant B/E ratio linked scanning to the identification and analysis of acylcarnitines in metabolic disease. 
  • Clinical pharmacology of benoxaprofen. 
  • Clorgyline and deprenyl attenuate striatal malonate and 3-nitropropionic acid lesions. 
  • Compound A uptake and metabolism to mercapturic acids and 3,3,3-trifluoro-2-fluoromethoxypropanoic acid during low-flow sevoflurane anesthesia: biomarkers for exposure, risk assessment, and interspecies comparison. 
  • Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease. 
  • Development of a novel series of styrylquinoline compounds as high-affinity leukotriene D4 receptor antagonists: synthetic and structure-activity studies leading to the discovery of (+-)-3-[[[3-[2-(7-chloro-2-quinolinyl)-(E)-ethenyl]phenyl][[3- (dimethylamino)-3-oxopropyl]thio]methyl]thio]propionic acid. 
  • Does dopamine contribute to striatal damage caused by impaired mitochondrial function? 
  • Dose-dependent metabolism of fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), an anesthetic degradation product, to mercapturic acids and 3,3,3-trifluoro-2-(fluoromethoxy)propanoic acid in rats. 
  • Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease. 
  • Effects of RSR13, a synthetic allosteric modifier of hemoglobin, alone and in combination with dizocilpine, on outcome from transient focal cerebral ischemia in the rat. 
  • Effects of a synthetic allosteric modifier of hemoglobin oxygen affinity on outcome from global cerebral ischemia in the rat. 
  • Effects of two nonsteroidal anti-inflammatory drugs, indomethacin and oxaprozin, on the kidney. 
  • Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. 
  • Evidence for metabolism of fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), a sevoflurane degradation product, by cysteine conjugate beta-lyase. 
  • First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. 
  • First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial. 
  • Gastrointestinal microbleeding: comparisons between benoxaprofen and other nonsteroidal antiinflammatory agents. 
  • Identification of csypyrone B1 as the novel product of Aspergillus oryzae type III polyketide synthase CsyB. 
  • Induction of stress proteins in cultured myogenic cells. Molecular signals for the activation of heat shock transcription factor during ischemia. 
  • Inhibition of Factor Xa : a potential target for the development of new anticoagulants. 
  • Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot. 
  • Inter-relations between 3-hydroxypropionate and propionate metabolism in rat liver: relevance to disorders of propionyl-CoA metabolism. 
  • Interrelations between C4 ketogenesis, C5 ketogenesis, and anaplerosis in the perfused rat liver. 
  • Intrinsic Xenobiotic Resistance of the Intestinal Stem Cell Niche. 
  • L-carnitine enhances excretion of propionyl coenzyme A as propionylcarnitine in propionic acidemia. 
  • Lactobacillus reuteri DSM 20016 produces cobalamin-dependent diol dehydratase in metabolosomes and metabolizes 1,2-propanediol by disproportionation. 
  • Lysophosphatidic acid stimulates cell growth by different mechanisms in SKOV-3 and Caov-3 ovarian cancer cells: distinct roles for Gi- and Rho-dependent pathways. 
  • MRP4-mediated regulation of intracellular cAMP and cGMP levels in trabecular meshwork cells and homeostasis of intraocular pressure. 
  • N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. 
  • Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. 
  • Novel constructs for thrombin inhibition. 
  • Opposite modulation of capsaicin-evoked substance P release by glutamate receptors. 
  • Parenteral nutrition in propionic and methylmalonic acidemia. 
  • Pharmacological correction of hypothermic P(50) shift does not alter outcome from focal cerebral ischemia in rats. 
  • Post-ischemic RSR13 amplifies the effect of dizocilpine on outcome from transient focal cerebral ischemia in the rat. 
  • Propionate-induced changes in cardiac metabolism, notably CoA trapping, are not altered by l-carnitine. 
  • Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription. 
  • Rapid cross-linking of elastin-like polypeptides with (hydroxymethyl)phosphines in aqueous solution. 
  • Role of cytochrome P4503A in cysteine S-conjugates sulfoxidation and the nephrotoxicity of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in rats. 
  • Role of prostacyclin in the cardiovascular response to thromboxane A2. 
  • Short chain fatty acids induce UCP2-mediated autophagy in hepatic cells. 
  • Stereospecific synthesis, assignment of absolute configuration, and biological activity of the enantiomers of 3-[[[3-[2-(7-chloroquinolin-2-yl)-(E)-ethenyl]phenyl] [[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]propionic acid, a potent and specific leukotriene D4 receptor antagonist. 
  • The G Protein-Coupled Estrogen Receptor Agonist G-1 Inhibits Nuclear Estrogen Receptor Activity and Stimulates Novel Phosphoproteomic Signatures. 
  • Thyroid hormones and 3,5-diiodothyropropionic acid: new keys for new locks. 
  • Tissue distribution studies of [18F]haloperidol, [18F]-beta-(4-fluorobenzoyl)propionic acid, and [82Br]bromperidol by external scintigraphy. 
  • Vascular endothelial tissue factor pathway inhibitor kinetics in culture following exposure to DX-9065a--a selective and direct factor Xa inhibitor. 
  • Visualizing reaction pathways in photoactive yellow protein from nanoseconds to seconds.